TrialRMD open2020

Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study.

Philip J Mease et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.